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Increasing trends for invasive infections with 
extended-spectrum cephalosporin-resistant (ESC-R) 
Enterobacteriaceae have been described in many coun-
tries worldwide. However, data on the rates of ESC-R 
isolates in non-invasive infections and in the outpa-
tient setting are scarce. We used a laboratory-based 
nationwide surveillance system to compare temporal 
trends of ESC-R rates in Escherichia coli and Klebsiella 
pneumoniae for in- and outpatients in Switzerland. 
Our data showed a significant increase in ESC-R rates 
from 1% to 5.8% in E. coli (p<0.001) and from 1.1% to 
4.4% in K. pneumoniae (p=0.002) during an eight-year 
period (2004–2011). For E. coli, the increase was sig-
nificantly higher in inpatients (from 1.2% to 6.6%), in 
patients residing in eastern Switzerland (from 1.0% to 
6.2%), in patients older than 45 years (from 1.2% to 
6.7%), and in male patients (from 1.2% to 8.1%). While 
the increase in inpatients was linear (p<0.001) for 
E. coli, the increase of ESC R K. pneumoniae isolates 
was the result of multiple outbreaks in several insti-
tutions. Notably, an increasing proportion of ESC-R 
E. coli was co-resistant to both trimethoprim-sul-
famethoxazole and quinolones (42% in 2004 to 49.1% 
in 2011, p=0.009), further limiting the available oral 
therapeutic options.
Introduction
Extended-spectrum cephalosporins (ESCs), such as 
those of third-generation (3GC, e.g. ceftriaxone, cefo-
taxime, ceftazidime) and fourth-generation (4GC, 
e.g. cefepime), are frequently used antibiotics for the 
treatment of severe infections, because of their ample 
spectrum, strong bactericidal activity, and low toxicity. 
However, during the past three decades, an increasing 
number of ESC-resistant (ESC-R) Gram-negative patho-
gens have been reported worldwide [1].
Several mechanisms such as production of extended-
spectrum beta-lactamases (ESBLs), chromosomal 
(cAmpCs) or plasmid-mediated AmpCs (pAmpCs) 
or carbapenemases may lead to phenotypic resist-
ance to ESCs. However, since their first description in 
1983, ESBLs have been recognised as the most preva-
lent mechanism responsible for resistance to ESCs in 
Enterobacteriaceae. While ESBLs during the 1990s were 
mainly described in Klebsiella pneumoniae isolates 
causing nosocomial outbreaks, ESBL-producing E. coli 
causing community-acquired infections (especially uri-
nary tract infections (UTIs)) nowadays also represent a 
serious challenge for the therapeutic armamentarium 
[2]. According to the Infectious Diseases Society of 
America (IDSA), ESBL-producing Klebsiella spp. and 
E. coli belong to the six most important multidrug-
resistant (MDR) pathogens for which new therapies are 
urgently needed [3]. 
The prevalence of ESC-R Enterobacteriaceae varies 
worldwide. In 2009, 39% of E.coli isolated from inten-
sive care patients in the Asian/Pacific area were ESBL 
producers, while rates were lower in Latin America 
(25%), Europe (16.3%) and North America (8.7%) [4]. 
As described by the European Antimicrobial Resistance 
Surveillance Network (EARS-Net), the prevalence rate 
of ESC-R Enterobacteriaceae causing invasive infec-
tions increased significantly from 2007 to 2010 in 
half of the reporting countries, but to different lev-
els. For instance, while the rates in 2010 were below 
5% in Scandinavia and Iceland, rates above 10% were 
found in 10 European countries (Bulgaria, Cyprus, 
Czech Republic, Greece, Hungary, Italy, Latvia, Malta, 
Romania and Spain) [5]. However, most surveillance 
programmes have taken into consideration only iso-
lates responsible for invasive infections in hospital-
ised patients [6], and only a few studies at national 
and local level have described rates of ESBL producers 
in community-acquired UTIs or bloodstream infections 
(BSIs) [7-10]. As a result, data regarding the temporal 
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trends of antibiotic resistance in the community are 
still needed. 
In this study, we describe in detail the temporal trends 
of ESC-R E. coli and K. pneumoniae isolates in hospi-
tal and community settings in Switzerland during an 
eight-year epidemiological study performed using the 
data of the Swiss Antibiotic Resistance Surveillance 
database ANRESIS [11]. 
Methods
Data collection
Antibiotic resistance data for E. coli and K. pneumo-
niae isolates were analysed using the ANRESIS data-
base [11]. The ANRESIS programme collects all routine 
antibiotic resistance data from currently 22 clinical 
microbiology laboratories located in Switzerland. The 
ANRESIS laboratories are homogeneously distributed 
across the country. They include university laborato-
ries, representing isolates mainly from tertiary-care 
hospitals, as well as cantonal and private laboratories, 
representing data from smaller hospitals and outpa-
tient clinics. They send antimicrobial susceptibility 
test results (AST) of all routinely performed analyses, 
including isolates from none-sterile sites. 
From 2004 to 2010, all participating laboratories inter-
preted their ASTs according to the Clinical Laboratory 
Standards Institute (CLSI) criteria in use at that time 
[12]. During 2011, five of the 11 laboratories included in 
this study changed their breakpoints according to the 
European Committee of Antimicrobial Susceptibility 
Testing (EUCAST) [13]. All institutions participated in at 
least one quality control programme from the United 
Kingdom National External Quality Assessment Service 
(UK NEQAS), and/or the National External Quality 
Program of the Institute of Medical Microbiology, Zurich 
[14]. AST results from each laboratory were sent on a 
regular basis, weekly or monthly, to the central data-
base located at our institution (Institute for Infectious 
Diseases of the University of Bern). 
For the present analysis, we used only data from the 
11 laboratories sending data during the whole study 
period. These laboratories were representative for 
Switzerland. Moreover, hospitals performing fewer 
than 200 microbiological samples per year were 
excluded. Only clinical samples were analysed. When 
there were multiple isolates with an identical resist-
ance pattern from the same patient and calendar year, 
only the first was included into the analysis. According 
to the hospital statistics of Switzerland for the year 
2007 [16] and the statistics of Swiss physicians 2009 
[17], the restricted data used for this analysis repre-
sent 30% of acute-care hospital beds in Switzerland 
and 11.2% of all Swiss family physicians. The number 
of BSIs was extrapolated using the 30% coverage of 
acute-care hospitals in this study.
Interpretation of the results 
Resistant isolates were defined as those that were 
resistant or had intermediate susceptibility against the 
antibiotic tested. E. coli and K. pneumoniae isolates 
resistant to at least one 3GC and/or 4GC antibiotic 
were defined as ESC-R. The selection of 3GC and/or 
4GC antibiotics tested differed between laboratories. If 
one antibiotic of an antibiotic class (e.g. quinolones or 
carbapenems) was resistant, the antibiotic class was 
classified as resistant. Results were stratified accord-
ing to geographical region, in- versus outpatients 
(where outpatient was defined as a person attending 
a medical practice or outpatient clinic), age and sex 
of the patient, and whether the isolate was from UTI 
or BSI. For inpatients, nosocomial infection data (i.e. 
sample(s) positive for ESC-R isolates at least three 
days after hospitalisation) were analysed separately. 
To examine seasonal trends, the period from April to 
September was defined as ‘summer season’, whereas 
that from October to March was defined as ‘winter sea-
son’. To compare prevalence rates of ESC-R E. coli and 
confirmed ESBL-positive E. coli, we used data from our 
own institution for the years 2009 and 2010. In this 
case, detection of ESBL producers was performed by 
double-disk synergy test (i.e. ceftriaxone, ceftazidime, 
cefpodoxime discs combined with an amoxicillin-clavu-
lanate disc, distance centre-to-centre 20 mm). 
Statistical analysis 
To calculate 95% confidence intervals (CIs) of pro-
portions, we used the modified Wald method [18]. 
Proportions were compared using two-tailed chi-square 
test or Fisher’s exact test using Epi info Version 3.4.3 
(Centers for Disease Control and Prevention, Atlanta, 
United States). We analysed the time trends with linear 
regression using GraphPad Prism Version 5.04.
Results
The overall study included 160,010 E. coli and 21,290 
K. pneumoniae isolates. ESBL confirmation was done 
for 225 ESC-R E. coli and 48 ESC-R K. pneumonia iso-
lated during the years 2009 and 2010 at the University 
Hospital of Bern. Of these, 210 (93.3%) E. coli and 46 
(95.8%) K. pneumoniae isolates were confirmed as 
ESBL producers by the double disc synergy test. 
During the eight-year period, a total of 63,743 E. coli 
(39.8%) and 11,083 (52.1%) K. pneumoniae were 
isolated from hospitalised patients from 34 differ-
ent hospitals, and 96,267 E. coli (60.2%) and 10,207 
K. pneumoniae (47.9%) isolates were collected from 
outpatients. Of the outpatient samples, 45,395 (47.2%) 
of E. coli isolates and 4,746 (46.5%) of K. pneumoniae 
isolates were collected in outpatient clinics, the rest 
were collected by general physicians. 
Escherichia coli 
Between 2004 and 2011, the prevalence of ESC-R E. coli 
increased significantly from 1.0% to 5.8% (p<0.001). 
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Table
Number and proportion of Escherichia coli and Klebsiella pneumoniae isolates with extended-spectrum cephalosporin 
resistance, Switzerland, 2004 and 2011
Escherichia coli Klebsiella pneumoniae
2004 2011
Pa
2004 2011
Pa
n/all (%) n/all (%) n/all (%) n/all (%)
Switzerland all 157/15,469 (1.0) 1,425/24,631 (5.8) <0.001 23/2,070 (1.1) 153/3,490 (4.4) 0.002
In- outpatient Pb=0.027 Pb=0.189
Inpatients 81/7,012 (1.2) 582/8,846 (6.6) <0.001 16/1,163 (1.4) 87/1,659 (5.2) 0.007
Outpatients 76/8,457 (0.9) 843/15,785 (5.3) <0.001 7/907 (0.8) 66/1,831 (3.6) <0.001
Hospital size Pb=0.457 Pb=0.733
<200 beds (n=4) 28/2,827 (1.0) 251/3,883 (6.5) <0.001 5/389 (1.3) 30/657 (4.6) 0.030
200–500 beds (n=12) 27/2,730 (1.0) 202/3,310(6.1) <0.001 6/464 (1.3) 37/645 (5.7) 0.020
>500 beds (n=18) 26/1,455 (1.8) 129/1,653 (7.8) <0.001 5/310 (1.6) 20/357 (5.6) 0.005
Departments Pb=0.546 Pb=0.451
Intensive care unit 5/398 (1.3) 35/500 /7.0) <0.001 1/134 (0.8) 10/190 (5.3) 0.261
Others 76/6,614 (1.2) 547/8,346 (6.6) <0.001 15/1,029 (1.5) 77/1,469 (5.2) 0.006
Outpatients Pb=0.399 Pb=0.117
Outpatient clinics 33/3,743 (0.9) 360/7,255 (5.0) <0.001 3/417 (0.7) 35/824 (4.3) 0.002
General physicians 43/4,714 (0.9) 483/8,530 (5.7) <0.001 4/490 (0.8) 31/1,007 (3.1) 0.001
Regionsc Pb=0.037 Pb=0.417
Eastern Switzerland 94/9,161 (1.0) 896/14,402 (6.2) <0.001 18/1,364 (1.3) 89/2,237 (4.0) 0.004
South-western 
Switzerland 63/6,308 (1.0) 529/10,229 (5.2) <0.001 5/706 (0.7) 64/1,253 (5.1) 0.007
 Sampled Pb=0.942 pb=0.869
 Blood 12/795 (1.5) 68/1,095 (6.2) <0.001 2/145 (1.4) 8/226 (3.5) 0.047
 Urine 119/12,815 (0.9) 1,112/20,815 (5.3) <0.001 10/1,386 (0.7) 104/2,523 (4.1) <0.001
 Respiratory 3/373 (0.8) 57/547 (10.4) <0.001 2/307 (0.7) 18/449 (4.0) 0.33
 Wounds 18/1,293 (1.4) 156/1,167 (13.4) <0.001 6/355 (1.7) 22/308 (7.1) 0.09
 Age group (years) Pb<0.001 Pb=0.432
 <2 9/860 (1.0) 27/857 (3.2) 0.018 3/122 (2.5) 6/120 (5.0) 0.737
 2–15 12/1,204 (1.0) 68/1,300 (5.2) <0.001 2/62 (3.2) 4/75 (5.3) 0.660
 15–45 26/4,054 (0.6) 223/5,909 (3.8) <0.001 2/311 (0.6) 20/452 (4.4) 0.016
 45–65 30/3,070 (1.0) 313/4,983 (6.3) <0.001 6/453 (1.3) 68/1,454 (4.7) 0.017
 >65 80/6,281 (1.3) 794/11,582 (6.9) <0.001 10/1,122 (0.9) 55/1,389 (4.0) 0.002
 Sexe Pb<0.001 Pb=0.138
 Female 111/11,738 (1.0) 958/18,825 (5.1) <0.001 14/1,305 (1.1) 75/2,238 (3.4) 0.010
 Male 46/3,725 (1.2) 467/5,800 (8.1) <0.001 9/764 (1.2) 78/1,252 (6.2) <0.001
a  Significance level indicating the probability that the slope of the linear regression using data of all years between 2004 and 2011 equals 0.
b  Significance level indicating the probability that the slopes in the subgroups are equal by chance.
c  South-western Switzerland includes the cantons Geneva, Vaud, Neuchâtel, Jura, Fribourg, Valais and Ticino; eastern Switzerland includes 
all other cantons.
d  Other sample locations are not shown, therefore figures do no sum up to the total number.
e  Sex was not specified for six E. coli isolates.
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Figure 1
Co-resistance rates for ESC-R and non-ESC-R Escherichia coli and Klebsiella pneumoniae isolates, Switzerland, 2004–11
ESC-R: extended-spectrum cephalosporins-resistant; SXT: trimethoprim-sulfamethoxazole. 
Resistance rates and 95% confidence intervals for different antibiotics for ESC-R and non-ESC-R E. coli and K. pneumoniae for the years 2004 
to 2011. Fosfomycin and nitrofurantoin were not tested against K. pneumoniae isolates. Because of low numbers data are not shown for 
fosfomycin for the years 2004 to 2007. P values are given for significant trends only (p<0.05).
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Figure 2
Increase in ESC-R rates in Escherichia coli and Klebsiella pneumoniae in 34 hospitals in Switzerland, 2004–11
ESC-R: extended-spectrum cephalosporins-resistant; p: significance for correlation; r: Pearson’s correlation index.
A. Means and standard error of the means of ESC-R prevalence rates in 34 Swiss hospitals from 2004 to 2011. The linear regression showed 
significant increase over time for E. coli and K. pneumonia (p<0.001 for both), correlation was linear for E. coli (p<0.001) and K. pneumoniae 
(p=0.007).
B. Rates of ESC-R isolates for individual hospitals. While the increase of ESC-R rates was steady and comparable in all hospitals for E. coli, we 
observed high variability between different years and hospitals for K. pneumoniae. 
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This time trend was linear and without seasonality 
(data not shown). This increase in rates of ESC-R iso-
lates was observed in all patient groups analysed 
and was significantly more pronounced in inpatients 
(p=0.027), in eastern Switzerland (p=0.037), in male 
patients (p<0.001), and those older than 45 years 
(p<0.001) (Table). There was no difference between 
patients under 15 and those 15–45 years of age, or 
between the age groups 45–65 years and over 65 
years, although there was a trend for lower resistance 
in children younger than two years compared with 
those 2–15 years-old (p=0.055). We noted a significant 
increase of ESC-R isolates (from 0.6% in 2004 to 3.5% 
in 2011; p<0.001) in female patients aged between 15 
and 45 years. In inpatients, we did not record differ-
ences between those with a nosocomial infection and 
those without (p=0.15). 
The absolute number of BSIs due to ESC-R E. coli 
increased from 12 in 2004 to 68 in 2011. Extrapolated 
to the overall Swiss population with 7.95 million inhab-
itants at the end of 2011 [19], we would expect that BSIs 
due to ESC-R E. coli increased from 40 (0.5/100,000 
inhabitants) to 227 (2.9/100,000 inhabitants) episodes 
per year.
The co-resistance rates to other antibiotic classes are 
shown in Figure 1. Rates were significantly higher for 
ESC-R than non-ESC-R E. coli isolates. Co-resistance did 
not differ between in- and outpatients (data not shown). 
For the non-ESC-R E. coli isolates, rates increased sig-
nificantly over time for sulfamethoxazole-trimethoprim 
(SXT; 20.9% in 2004 versus 24.0% in 2011, p<0.001), 
quinolones (10.3% in 2004 versus 17.4% in 2011, 
p<0.001), the combined resistance to SXT and qui-
nolones (7.1% in 2004 versus 10.1% in 2011, p<0.001), 
piperacillin-tazobactam (1.6% in 2004 v versus. 3.0% 
in 2011, p=0.005), and gentamicin (3.8% in 2004 ver-
sus 4.9% in 2011, p<0.001). For the ESC-R E. coli, we 
observed an increase in co-resistance to gentamicin 
(28.2% in 2004 versus. 33.6% in 2011, p=0.013), SXT 
(52.9% in 2004 versus. 60.1% in 2011, p=0.015), and 
combined resistance to SXT and quinolones (42.0% in 
2004 versus 49.1% in 2011, p=0.009), and a non-sig-
nificant increasing resistance rate for quinolones alone 
(58.0% in 2004 versus 67.8% in 2010, p=0.06). 
Figure 3
Distribution of ESC-R Escherichia coli and Klebsiella pneumoniae isolates, by sampling location, Switzerland, 2004-2011
ESC-R: extended-spectrum cephalosporins-resistant.
* p<0.001.
ESC-R E. coli as well as ESC-R K. pneumoniae were isolated mostly from urinary samples. ESC-R K. pneumoniae were isolated 2.2 times more 
frequently from respiratory or wound samples than ESC-R E. coli (p<0.001).
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Klebsiella pneumoniae 
Overall, from 2004 to 2011 ESC-R K. pneumoniae 
isolates increased significantly from 1.1% to 4.4% 
(p=0.002). The increase was comparable in all patient 
subgroups (Table) and significant and linear in inpa-
tients (Table, Figure 2A). However, in contrast to ESC-R 
E. coli, the Pearson’s correlation index was lower due 
to higher variability between different years in single 
hospitals (Figure 2B). Furthermore, ESC-R K. pneumo-
niae isolates were more frequently isolated from other 
sites than blood or urine than ESC-R E. coli (34.3% 
K. pneumoniae versus 17.4% E. coli, p<0.001). In par-
ticular, about two thirds of these non-blood, non-urine 
ESC-R K. pneumoniae were isolated from wounds or 
respiratory samples (Figure 3). 
As shown in Figure 1, co-resistance in ESC-R K. pneu-
moniae exceeded 50% for all antibiotic classes tested 
except for aminoglycosides (gentamicin 30.8% and 
amikacin 6.0%) and carbapenems (4.1%) in 2011. 
These resistance rates were significantly higher in 
ESC-R than in non-ESC-R K. pneumoniae isolates. 
While there was no significant trend in co-resistance 
in ESC-R K. pneumoniae, we observed a significant 
increase in resistance in non-ESC-R K. pneumoniae for 
amoxicillin-clavulanate (5.1% in 2004 versus 11.5% in 
2011, p=0.035), piperacillin-tazobactam (2.3% in 2004 
versus 8.3% in 2011, p=0.030), and for double resist-
ance to SXT and quinolones (2.5% in 2004 versus 5.3% 
in 2011, p=0.028).
Discussion
Increasing rates of ESC-R Enterobacteriaceae have 
been described worldwide, however most data rely on 
BSIs in inpatients [2,6,20]. Data on prevalence of ESC-R 
isolates among outpatients are rare and restricted 
to single years (e.g. France, 2006 [7]; Italy, 2003 [8]; 
Spain, 2006 [9]; Turkey, 2007 [10]). Only one of these 
studies compared rates of ESC-R Enterobacteriaceae 
among in- and outpatients [8], and data regarding 
temporal trends among outpatients are missing. Here, 
we present the temporal trends of ESC-R E. coli and 
K. pneumoniae among outpatients and compare the 
epidemiology of in- and outpatients from 2004 to 2011. 
E. coli
According to EARSS data, rates of ESC-R E. coli isolated 
from BSIs increased from 2.7% in 2003 to 8.2% in 2009 
[21]. Although such prevalence was lower in our popu-
lation (1.5% in 2004 and 6.2% in 2011), the increasing 
trend was comparable with the above European data. 
We calculated an annual incidence of 2.9/100,000 
cases of BSI due to ESC-R E. coli in 2011, which is in 
the same range as the average of 2.6/100,000 cases 
described in the 31 countries participating in EARSS in 
2007 [21]. The societal and economic burden of infec-
tions due to ESC-R E. coli is remarkable. Taking into 
consideration the morbidity and mortality data avail-
able in the literature, we would estimate 58 additional 
deaths and 1,131 additional hospital days attributable 
to BSI due to ESC-R E. coli in 2011 in Switzerland [22]. 
Extrapolating to other clinical manifestations, such as 
lower respiratory tract infections, skin and soft tissue 
infections and UTIs, we would expect 838 infections 
leading to 131 deaths and 9,233 additional days of hos-
pitalisation [23] in Switzerland during the year 2011.
Rates of ESC-R E. coli increased steadily in all patient 
subgroups analysed, but especially in patients older 
than 45 years, in male patients and inpatients. This 
observation probably reflects the higher prevalence 
of established risk factors for infections due to ESBL 
producers in these sub-populations, such as older age, 
diabetes mellitus, prostate disease, previous antibiotic 
use, indwelling catheters, recurrent UTIs, recent hospi-
tal admission and residence in long-term care facility 
[24-30]. 
Rates of ESC-R E. coli also increased significantly over 
time in lower risk populations, such as young women 
and outpatients. This correlates well with European 
studies demonstrating increasing faecal carriage rates 
of ESBL-producing E. coli in the outpatient setting 
[31-34]. In Switzerland, a recent study detected ESBL-
producing E. coli in 5.8% of routine stool samples from 
staff members of meat-processing companies [35], 
whereas as many as 15.2% of pigs and 17.1% of cattle 
at slaughter carried ESBL-producing E. coli, indicating 
that there is an established reservoir of these organ-
isms in farm animals in Switzerland [36]. 
Co-resistance in ESC-R E. coli is frequent and at least 
in part due to the fact that genes coding for the resist-
ance to different antibiotics are located on the same 
plasmids [6]. In our study, roughly half of ESC-R E. coli 
were resistant to both SXT and quinolones. Resistance 
rates to these antibiotics increased over time, whereas 
resistance to nitrofurantoin and fosfomycin did not 
increase between 2004 and 2011, indicating that both 
antibiotics are still a valuable alternative for non-com-
plicated UTIs [37]. For invasive infections, carbapenems 
are still a valuable option, but it is feared that spread of 
carbapenemase producers (e.g. KPC and NDM produc-
ers) will increase the incidence of MDR bacteria [38]. 
K. pneumoniae
K. pneumoniae is the second most frequent cause 
of Gram-negative BSIs after E. coli and often affects 
patients with impaired immune system such as 
patients with diabetes, alcohol problems and hospital-
ised patients with indwelling devices [5]. In our popu-
lation, BSIs due to K. pneumoniae in 2011 were eight 
times less frequent than those due to E. coli. 
As for E. coli, prevalence rates of ESC-R K. pneumo-
niae are increasing worldwide. Between 2007 and 2010 
rates of ESC-R K. pneumoniae increased significantly in 
nine of 28 countries participating in EARSS, leading to 
very different rates (from below 1% in northern coun-
tries to greater than 50% in some south-eastern coun-
tries) [6]. Restricting our analysis to blood cultures, we 
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observed an increase in ESC-R isolates from 1.4% in 
2004 to 3.5% in 2011 (p=0.05), which is comparable to 
the northern countries of Europe [5]. 
As for E. coli, rates of ESC-R K. pneumoniae increased 
in all patient subgroups but, in contrast to E. coli, 
there were no differences by age or sex. Resistance 
to other antibiotic classes was even higher than in 
E. coli. Indeed, ESC-R K. pneumonia resistance rates in 
2011 were above 50% for all antibiotics tested except 
aminoglycosides and carbapenems. Carbapenemase 
resistance in ESC-R K. pneumoniae increased from 0% 
to 4.1%, which was not significant (p=0.11). However, 
in view of the global epidemiology, this finding prob-
ably anticipates a worrisome expansion of these life-
threatening pathogens [39].
In contrast to E. coli, infections with ESC-R K. pneu-
moniae are still mainly hospital-associated [40], with 
outbreaks more frequently reported for ESC-R K. 
pneumonia than for ESC-R E. coli [41,42]. This is sup-
ported by our analysis demonstrating that the increase 
of infections due to ESC-R K. pneumoniae was more 
pronounced in inpatients, which is mainly due to the 
accumulation of multiple small outbreaks in single hos-
pitals (see Figure 2b). Several reasons for the higher 
frequency of outbreaks in K. pneumoniae have been 
postulated: (i) environmental contamination occurs 
significantly more often when the patient is carrying 
ESBL-producing K. pneumoniae compared with ESBL-
producing E. coli [41]; (ii) K. pneumoniae has a higher 
ability to persist in the environment due to the forma-
tion of biofilms [43]; (iii) some antiseptics (e.g. chlo-
rhexidine or hexamidine) are less effective against 
K. pneumoniae [44]. In addition, our data demonstrate 
that ESC-R K. pneumoniae were more frequently iso-
lated from wounds or the respiratory tract, which may 
facilitate transmission, when standard hygiene precau-
tions are not implemented.
Our study has several limitations. Because physicians 
frequently implement an empirical treatment for UTIs 
and provide a urine sample only if the infection does 
not improve, our analysis may overestimate the real 
incidence of ESC-R [45]. In addition, it is important 
to note that our study describes the epidemiology of 
ESC resistance, which includes ESBL, pAmpCs and 
cAmpCs. However, our data are consistent with those 
of the European Center for Disease Prevention and 
Control (ECDC), which also use ESC-R as a surrogate 
for ESBL production, demonstrating that 65 to 100% 
of ESC-R E. coli in Europe are ESBL producers [5]. We 
were not able to perform genetic analysis to confirm 
the presence of ESBL genes in our collection of iso-
lates. Performing phenotypic ESBL confirmation tests 
in a subset of our samples, we speculate that about 93 
to 96% of ESC-R isolates in Switzerland are true ESBL 
producers. However, the clinical impact of confirming 
ESBL production is debated, and newer guidelines 
even abstain from confirmatory tests and at least for 
clinical decisions completely rely on phenotypic resist-
ance testing results [46,47].
In conclusion, we demonstrate a significant increase of 
ESC-R E. coli and K. pneumoniae isolates in the period 
from 2004 to 2011 in Switzerland. This increase is com-
parable to other European countries. Our data allowed 
us to demonstrate an increase in ESC-R in non-invasive 
and in outpatient samples and to estimate the burden 
of disease in Switzerland. National surveillance should 
be implemented and maintained to monitor the spread 
of life-threatening MDR pathogens and support phy-
sicians in the implementation of correct and effica-
cious antibiotic treatments in community and hospital 
settings.
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